Does insurance cover Ozempic in New York?

If you’re exploring weight loss options or managing Type 2 diabetes, you’ve likely heard about the transformative results of GLP-1 medications like Wegovy, Ozempic, and Mounjaro. These injectable drugs have changed the landscape of weight management and diabetes care—but there’s one burning question on everyone’s mind: Will my insurance actually cover them?

The answer isn’t simple. Insurance coverage for these medications varies dramatically based on your insurance type, diagnosis, state, and even your employer’s specific plan. With monthly costs exceeding $1,000 without coverage, understanding your options is crucial before starting treatment.

This comprehensive guide breaks down exactly what you need to know about insurance coverage for GLP-1 medications in 2025, including coverage criteria, common denial reasons, state-by-state Medicaid differences, and affordable alternatives if your insurance says no.

Understanding GLP-1 Medications: What’s the Difference?

Before diving into insurance coverage, let’s clarify what these medications actually are and how they differ:

Ozempic (semaglutide) is FDA-approved exclusively for treating Type 2 diabetes. It helps lower blood sugar and has the added benefit of weight loss, though insurance won’t cover it for weight loss alone.

Wegovy (semaglutide) is the same active ingredient as Ozempic but is specifically FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight adults (BMI ≥27) with at least one weight-related condition like high blood pressure or Type 2 diabetes.

Mounjaro (tirzepatide) is approved for Type 2 diabetes and works on both GLP-1 and GIP receptors, often producing even more significant weight loss than semaglutide—though like Ozempic, it’s not FDA-approved for weight loss as a primary indication. (Note: Zepbound is the weight-loss version of tirzepatide.)

The key takeaway? Your diagnosis matters enormously for insurance coverage. Diabetes? You’ll likely get coverage for Ozempic or Mounjaro. Weight loss without diabetes? That’s where things get complicated.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: What to Expect in 2025

Coverage by Indication

Most commercial health plans (employer-sponsored or ACA Marketplace plans) follow a predictable pattern:

For Type 2 Diabetes: Ozempic and Mounjaro are typically covered as part of diabetes management. These medications are considered essential diabetes treatments, so insurers generally include them on their formularies—though almost always with prior authorization requirements and often as Tier 3 (non-preferred brand) or specialty tier drugs.

For Weight Loss: This is where coverage becomes inconsistent. Many employer health plans explicitly exclude anti-obesity medications as optional benefits due to high costs. According to recent data, a significant number of large employers opt out of covering weight-loss drugs entirely, viewing them as lifestyle rather than medical necessity.

When Wegovy is covered for weight loss, expect strict requirements:

• BMI ≥30 (or ≥27 with at least one weight-related comorbidity like hypertension, Type 2 diabetes, or sleep apnea)
• Documentation of 6+ months of supervised diet and exercise attempts
• Documented failure on lifestyle interventions or older weight-loss medications
• Age restrictions (typically 18+)
• Regular monitoring and proof of weight loss (usually ≥5% body weight) to continue coverage after initial 3–6 months

Prior Authorization: The Gatekeeper

Nearly all GLP-1 medications require prior authorization (PA), meaning your doctor must submit detailed documentation proving medical necessity before the insurer approves coverage. This process typically includes:

• Complete medical history and current BMI calculation
• Documentation of weight-related health conditions
• Records of previous weight-loss attempts (diet programs, exercise logs, medications tried)
• Lab results (A1c for diabetes, cholesterol panels, blood pressure readings)
• Physician’s letter of medical necessity

The PA review usually takes 5–10 business days, though it can stretch longer if additional information is requested. Many patients report frustration with this process—but it’s also where having a knowledgeable healthcare provider makes a significant difference.

At Klarity Health, our providers understand insurance requirements inside and out. We work directly with you to compile the necessary documentation, submit thorough prior authorizations, and follow up with insurers to expedite approvals. Our telehealth platform makes this process seamless—no office visits required, and we handle the insurance paperwork while you focus on your health goals.

Common Commercial Plans: A Snapshot

Aetna typically requires BMI ≥35 for Wegovy coverage (or BMI ≥30 with comorbidities), plus documented 6-month lifestyle intervention. Their clinical policy mandates periodic re-evaluation to confirm ongoing weight loss.

Cigna generally covers GLP-1 drugs only for FDA-approved indications—meaning Ozempic for diabetes gets covered, but Ozempic prescribed off-label for weight loss does not. For Wegovy, strict PA criteria apply, similar to Aetna.

UnitedHealthcare varies significantly by employer plan. Some UHC plans cover Wegovy with standard obesity criteria; others exclude all anti-obesity medications. Always check your specific Summary of Benefits.

Blue Cross Blue Shield coverage differs by state affiliate. Most BCBS plans include diabetes GLP-1s with PA, while obesity medication coverage is plan-dependent.

Medicare Coverage: Limited but Evolving

Here’s the frustrating reality for Medicare beneficiaries: Medicare Part D does not cover medications prescribed solely for weight loss. This is written into federal law—anti-obesity drugs are in the same excluded category as cosmetic medications.

The Cardiovascular Exception

There is one important loophole: As of March 2024, Medicare will cover Wegovy for cardiovascular risk reduction in patients with established cardiovascular disease and obesity. This means if you have a documented history of heart disease (previous heart attack, stroke, or significant cardiovascular risk factors) along with obesity, Medicare may cover Wegovy—but the prescription must indicate it’s for reducing CV risk, not weight loss.

This distinction matters. Your doctor must document that the medication is being prescribed to prevent heart attacks or strokes in a high-risk patient, not primarily for weight management (even though weight loss is a welcome side effect).

Medicare Part D and Diabetes

For diabetes management, Medicare Part D does cover Ozempic and Mounjaro. They’re typically placed on specialty tiers with higher copays or coinsurance (often 25–33% of the drug cost). Prior authorization is common, and many Part D plans require step therapy—meaning you must try metformin or other first-line diabetes medications before a GLP-1 is approved.

Medicare Advantage Plans

Some Medicare Advantage plans have begun offering limited coverage for anti-obesity medications as supplemental benefits in 2025, but this varies widely by plan and region. If weight loss is your goal and you’re on Medicare, research MA plans carefully during open enrollment—but don’t assume coverage is standard.

Medicaid Coverage: A State-by-State Patchwork

Medicaid coverage for GLP-1 medications is perhaps the most complex landscape to navigate. States have the option to cover anti-obesity drugs, and as of 2025, only about 13 states provide any Medicaid coverage for weight-loss medications—and even that number is shrinking.

States Covering Wegovy (With Heavy Restrictions)

New York Medicaid covers Wegovy through its NYRx formulary with strict prior authorization. Patients must meet BMI requirements (≥30 or ≥27 with comorbidities), document lifestyle interventions, and receive regular monitoring. Quantity limits apply (typically 4 pens per 28 days).

Pennsylvania Medicaid added Wegovy coverage in 2023 with comprehensive PA criteria—but here’s the catch: coverage is ending January 1, 2026, due to budget pressures. The state cited unsustainable costs as obesity drug spending skyrocketed. If you’re currently on Wegovy through PA Medicaid, you’ll need to transition to alternative options or self-pay in early 2026.

States NOT Covering Wegovy

Texas Medicaid explicitly excludes all obesity medications for adults (age ≥21). The state’s Vendor Drug Program classifies weight-loss drugs as non-covered, invoking the federal optional exclusion. Only pediatric patients (under 21) may request case-by-case exceptions through EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) provisions.

Florida Medicaid does not cover any anti-obesity medications. Only GLP-1s prescribed for Type 2 diabetes (Ozempic, Mounjaro) are covered, and only for that specific indication.

California provided limited Wegovy coverage through Medi-Cal in 2025 with strict PA requirements—but like Pennsylvania, California is discontinuing coverage effective January 1, 2026. This decision affects adult beneficiaries; pediatric coverage may continue under EPSDT.

Illinois Medicaid has not adopted coverage for anti-obesity drugs. While the state expanded coverage for state employees in 2023, Medicaid enrollees remain excluded.

Why Are States Dropping Coverage?

The pattern is clear: even states that initially covered GLP-1 weight-loss drugs are now pulling back due to explosive costs. These medications cost over $1,000 per patient per month, and with millions potentially eligible, the budget impact is staggering. States like California estimated annual costs exceeding $1 billion if just a fraction of eligible Medicaid enrollees accessed these drugs.

For Medicaid patients, this creates a challenging situation. If your state Medicaid doesn’t cover Wegovy, your options are limited to:

• Self-pay programs (see pricing section below)
• Patient assistance programs if you qualify by income
• Alternative weight-loss approaches covered by Medicaid (behavioral counseling, bariatric surgery in some states)

Understanding Common Denial Reasons—and How to Appeal

Even when your insurance theoretically covers GLP-1 medications, initial denials are frustratingly common. Here’s why claims get rejected and what you can do:

Top Denial Reasons

1. BMI doesn’t meet criteria. Many plans require BMI ≥30 (or ≥27 with comorbidities) documented by the prescribing physician. If your BMI calculation in medical records is borderline or the comorbidity isn’t clearly documented, expect a denial.

2. Insufficient documentation of lifestyle modification. Most insurers require proof you’ve tried diet and exercise under medical supervision for at least 6 months—and failed to lose adequate weight. Without detailed records (weight logs, dietitian notes, exercise plans), the PA gets denied.

3. Missing step therapy requirements. Some plans require you to try older, cheaper weight-loss medications first (like phentermine or orlistat) before approving a GLP-1. For diabetes, you may need to document trying metformin or another oral diabetes drug first.

4. Off-label use. Prescribing Ozempic (diabetes drug) for weight loss in a non-diabetic patient is off-label and virtually always denied. Insurers strictly enforce FDA-approved indications—if you need weight loss, the prescription must be for Wegovy, not Ozempic.

5. Plan exclusion. Some employer plans simply exclude ‘weight control’ drugs entirely in their formulary. This is a blanket exclusion—no amount of documentation will overturn it unless your employer adds the benefit.

How to Successfully Appeal

If your prior authorization is denied, don’t give up immediately. Appeal success rates vary, but with proper documentation, many denials can be overturned:

Gather additional evidence: Work with your doctor to compile comprehensive records—updated BMI measurements, documented comorbidities with lab values, detailed notes from your weight-loss attempts, and a strong letter of medical necessity explaining why this medication is essential for your health.

Cite clinical guidelines: Reference medical society guidelines (like American Association of Clinical Endocrinology recommendations) that support GLP-1 use for your specific situation.

Document health risks: Emphasize obesity-related complications (diabetes risk, cardiovascular disease, sleep apnea severity) that make treatment urgent.

Request a peer-to-peer review: Your doctor can request to speak directly with the insurance company’s medical director to explain the case—this often helps overcome denials based on misunderstanding.

Escalate if necessary: If the first appeal fails, file a second-level appeal. For employer plans, you can eventually request an external review by an independent medical reviewer.

Klarity Health simplifies the appeal process. Our providers have extensive experience crafting compelling appeals and can guide you through every step. We know what documentation insurers need, and we’ll work persistently on your behalf. Plus, since we offer transparent pricing for both insured and self-pay patients, you always have options even if insurance coverage falls through.

Self-Pay Options: Affording GLP-1s Without Insurance

If insurance won’t cover your medication—or coverage is too unreliable—self-pay has become significantly more accessible in 2025 thanks to new manufacturer programs and discount platforms.

GoodRx Partnership Pricing (2025)

In November 2025, GoodRx announced a groundbreaking partnership with Novo Nordisk offering:

• $199/month for the first two fills of Wegovy or Ozempic
• $349/month ongoing for standard maintenance doses
• Available at nearly all major pharmacies nationwide

This represents approximately a 70% discount off list prices and makes these medications accessible to many self-paying patients for the first time.

Manufacturer Savings Programs

Novo Nordisk NovoCare Programs:

• Savings Card (for insured patients): Reduces copays to as low as $0–$25 per month (maximum savings $225/month) for commercially insured patients whose plans cover the drug. Cannot be used with government insurance.
• Cash-Pay Program: Wegovy available for $349/month directly through Novo’s access program (down from previous $499 pricing).
• Patient Assistance Program: Free medication for uninsured or underinsured patients meeting income criteria (typically ≤400% federal poverty level).

Eli Lilly Programs (Mounjaro/Zepbound):

• Savings Card: $25/month for insured patients with Type 2 diabetes (covers up to $500 of the cost).
• LillyDirect Cash Program: Single-dose vials of Zepbound (tirzepatide for weight loss) now available for $299–$449/month depending on dose—a significant reduction from previous $500+ pricing.
• Patient Assistance Program: Provides medication at no cost for eligible low-income, uninsured patients.

Telehealth + Transparent Pricing

Many patients are discovering that telehealth platforms offering bundled services provide the most predictable and affordable path to GLP-1 treatment.

Klarity Health offers a straightforward approach: We accept both insurance and self-pay, with transparent pricing you’ll know upfront. Whether you’re navigating insurance coverage or choosing to pay out-of-pocket, our providers guide you to the most cost-effective option for your situation. We can prescribe FDA-approved medications and connect you with manufacturer savings programs and discount cards to minimize your costs. With virtual appointments available across multiple states, you can access care without the hassle of traditional office visits—and our team handles prior authorizations and insurance follow-up so you don’t have to.

What About Compounded Semaglutide?

You may have seen ads for much cheaper ‘compounded semaglutide’ from various telehealth or wellness clinics. While these compounded versions can cost $200–$400 monthly, proceed with caution.

Compounded medications are not FDA-approved. They’re mixed by specialty pharmacies and may vary in potency, purity, and safety. The FDA has issued warnings about quality concerns with compounded GLP-1s. Additionally, insurance never covers compounded medications, and you have no guarantee of consistency batch-to-batch.

For most patients, FDA-approved Wegovy, Ozempic, or Mounjaro—accessed through manufacturer programs or discount platforms—remains the safer, more reliable choice.

Telehealth Coverage: Good News for Virtual Weight Loss Programs

Here’s some genuinely good news: Telehealth visits for weight management and diabetes care are widely covered by insurance in 2025.

Over 40 states have enacted telehealth parity laws requiring insurers to cover virtual visits the same as in-person consultations. Since the COVID-19 pandemic, telehealth has become standard practice, and most major insurers—including Medicare—now routinely cover telemedicine appointments.

What This Means for You

If your insurance covers nutritional counseling, obesity medicine consultations, or diabetes management visits, those services should be covered whether delivered in-person or via telehealth—often at the same copay.

Key considerations:

• Use in-network providers: Make sure your telehealth platform or provider is in your insurance network. Many plans now contract directly with telehealth companies.
• Live video typically required: Most insurers require real-time video consultations (not just phone or messaging) for coverage.
• Prior authorization handled remotely: Your virtual provider can submit PAs and appeals just like a traditional doctor.
• Prescription coverage separate: While the telehealth visit itself is covered, the medication prescription fills at your pharmacy under your pharmacy benefit (subject to all the coverage rules discussed above).

Klarity Health is designed around telehealth convenience. Our licensed providers conduct comprehensive virtual evaluations, prescribe appropriate medications, and coordinate all aspects of treatment—including insurance verification, prior authorizations, and ongoing monitoring. Whether your insurance covers GLP-1 medications or you’re self-paying, you’ll have transparent pricing and expert guidance throughout your weight loss journey. We make accessing evidence-based obesity treatment as simple as logging into a video call.

State-by-State Medicaid Coverage: Quick Reference

Understanding your state’s Medicaid policy is crucial if you’re a beneficiary. Here’s a quick breakdown for major states:

For diabetes medications (Ozempic, Mounjaro), coverage is much more consistent across state Medicaid programs—though prior authorization is still typically required.

Medicare vs. Medicaid vs. Commercial: Coverage Comparison

The trend is clear: Diabetes indications receive broad coverage; obesity treatment does not—at least not yet. Advocacy groups are pushing for expanded coverage, arguing obesity is a chronic disease that deserves parity with conditions like diabetes, but cost concerns continue to dominate insurer decisions.

Tips for Maximizing Your Coverage

1. Get your diagnosis right. If you have Type 2 diabetes, prediabetes, metabolic syndrome, or cardiovascular disease along with obesity, make sure these are clearly documented in your medical record. The more comorbidities, the stronger your case.

2. Document everything. Keep detailed records of all weight-loss attempts—diet logs, exercise programs, previous medications, counseling sessions. Your doctor will need this for the PA.

3. Work with knowledgeable providers. Physicians experienced in obesity medicine know exactly what insurers require and how to present your case compellingly. Platforms like Klarity Health specialize in this.

4. Don’t accept the first denial. Many initial PAs are denied due to missing information. Provide additional documentation and appeal.

5. Explore all savings programs. Even if insurance covers your medication, manufacturer copay cards might reduce your out-of-pocket costs to nearly zero. Check eligibility for every program.

6. Consider total cost of care. Sometimes self-pay with manufacturer discounts ($350/month) is actually less than your insurance copay for a specialty-tier medication (which might be 33% coinsurance on a $1,000+ drug). Do the math.

7. Re-evaluate annually. Insurance plans change every year. If your current plan doesn’t cover obesity medications, check if other options during open enrollment might—or if your employer is adding this benefit.

The Future of GLP-1 Insurance Coverage

Coverage is evolving rapidly. Several trends suggest potential improvement ahead:

Employer interest is growing. Some large employers are adding obesity medication coverage as they recognize the long-term cost savings from preventing diabetes, heart disease, and other complications.

Medicare expansion possible. There’s ongoing discussion about changing federal law to allow Medicare to cover anti-obesity medications. The recent CV risk exception is a step in that direction.

Pricing pressure. With new competition entering the GLP-1 market and manufacturers lowering self-pay prices to retain patients, insurers may face pressure to cover these increasingly affordable medications.

Clinical evidence mounting. As studies continue demonstrating the health benefits and cost-effectiveness of treating obesity with GLP-1s, payers may become more willing to cover them.

However, in the near term (2025–2026), we’re seeing a pullback—states cutting Medicaid coverage, employers hesitating due to cost, and insurers maintaining strict controls. Patients should plan accordingly.

Your Next Steps

If you’re considering GLP-1 medications for weight loss or diabetes management:

1. Check your specific coverage. Log into your insurance portal and review your prescription formulary. Look for ‘prior authorization requirements’ for each medication.

2. Talk to your doctor. Discuss whether you meet medical criteria for these medications and whether they’re appropriate for your health goals.

3. Consider telehealth options. Virtual care often provides faster access, expert guidance through insurance hurdles, and transparent pricing whether you’re using insurance or paying cash.

4. Explore savings programs early. If insurance won’t cover your medication, research manufacturer programs, GoodRx pricing, and patient assistance options before starting treatment so you know your costs upfront.

5. Be prepared to advocate. You may need to be persistent with insurance companies, provide additional documentation, or appeal denials. Don’t give up if weight loss medication is medically appropriate for you.

How Klarity Health Can Help

Navigating insurance coverage for weight loss medications shouldn’t require a PhD in healthcare policy. Klarity Health removes the complexity by offering:

• Expert providers who understand insurance requirements and how to build strong prior authorization cases
• Both insurance and cash-pay options, with transparent pricing you’ll know before your first appointment
• Convenient telehealth access—no office visits, no waiting rooms, care available across multiple states
• Complete insurance coordination, including PA submissions, appeals, and follow-up
• Connection to savings programs and manufacturer assistance to minimize your costs
• Ongoing support and monitoring to ensure treatment success

Whether your insurance covers GLP-1 medications or you’re exploring self-pay options, Klarity Health provides expert guidance and accessible care to help you achieve your weight loss and health goals.

Ready to explore your options? Connect with a Klarity Health provider today to discuss the best path forward for your situation—we’ll help you understand what your insurance covers and find the most affordable option for evidence-based weight loss treatment.

Frequently Asked Questions

Does Medicare cover Wegovy for weight loss?
No, Medicare Part D does not cover medications prescribed solely for weight loss due to federal law. However, Medicare will cover Wegovy if prescribed specifically for cardiovascular risk reduction in patients with established heart disease and obesity.

Why won’t my insurance cover Ozempic for weight loss?
Ozempic is FDA-approved only for Type 2 diabetes, not weight loss. Insurance companies strictly enforce FDA-approved indications. For weight loss, you need a prescription for Wegovy (same active ingredient, different indication) if your plan covers obesity treatment.

How long does prior authorization take?
Typical PA review takes 5–10 business days, though it can extend to 2–3 weeks if the insurer requests additional documentation. Some plans offer expedited review (72 hours) for urgent situations.

Can I use a manufacturer coupon with Medicaid?
No. Federal law prohibits using manufacturer copay cards or coupons with any government insurance (Medicaid, Medicare, TriCare). These savings programs are only available for commercially insured or self-pay patients.

What’s the cheapest way to get Wegovy without insurance?
As of late 2025, the GoodRx-Novo Nordisk partnership offers the best pricing: $199/month for your first two fills, then $349/month ongoing. Alternatively, Novo’s patient assistance program provides free medication if you meet income eligibility requirements.

Do all states’ Medicaid programs cover the same medications?
No. Medicaid coverage varies dramatically by state. Each state creates its own formulary and coverage rules. For obesity medications specifically, only a minority of states (~13) provide any coverage, and even those are implementing strict restrictions or ending coverage due to costs.

📅 RESEARCH CURRENCY STATEMENT (Verified as of December 17, 2025)

Top 5 Citations:

1. Aetna Clinical Policy Bulletin – Weight Loss GLP-1 Agonists (May 2024): Official insurer prior authorization criteria detailing BMI requirements, 6-month supervised lifestyle intervention, and coverage limitations. www.aetna.com

2. California DHCS Medi-Cal Announcement (December 2025): Official state notice that Medi-Cal will discontinue coverage for Wegovy, Saxenda, and Zepbound for weight loss effective January 1, 2026, due to budget constraints. www.cmadocs.org

3. GoodRx Press Release via BusinessWire (November 17, 2025): Announcement of partnership with Novo Nordisk providing $199/month introductory pricing for Wegovy and Ozempic, with ongoing $349/month pricing at retail pharmacies. www.businesswire.com

4. KFF Issue Brief – Medicaid Coverage of GLP-1s (November 4, 2024): Comprehensive research report documenting that only 13 states cover obesity GLP-1 medications under Medicaid, all with strict prior authorization and BMI criteria; details federal exclusion options. www.kff.org

5. Pennsylvania Health Law Project (2024): Consumer advocacy documentation of Pennsylvania Medicaid’s coverage criteria for Wegovy (BMI ≥30 or ≥27 with comorbidities, documented lifestyle intervention) and subsequent announcement of coverage termination in January 2026. www.phlp.org

All formulary information, pricing data, and coverage policies verified as current through December 17, 2025. Insurance policies change frequently—always verify current coverage with your specific plan before starting treatment.

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499